Literature DB >> 20434827

Mifepristone combined with misoprostol versus intra-amniotic injection of ethacridine lactate for the termination of second trimester pregnancy: a prospective, open-label, randomized clinical trial.

Shuping Hou1, Qinfang Chen, Lanrong Zhang, Aihua Fang, Linan Cheng.   

Abstract

OBJECTIVES: To compare the effectiveness and safety of mifepristone/misoprostol versus intra-amniotic injection of ethacridine lactate for the termination of second trimester pregnancy. STUDY
DESIGN: 210 women requesting voluntary termination of pregnancies at between 16 and 24 weeks of gestation were randomly assigned into two groups. Group 1 (MM) received a single oral dose of 200 mg mifepristone and, 36-48 h later, 400 microg of misoprostol vaginally, with up to three additional oral doses of 400 microg misoprostol every 12 h. Group 2 (EL) received an intra-amniotic injection of 100mg ethacridine lactate. The primary outcome was successful abortion rate. Secondary outcomes included the difference in the induction-to-abortion interval and the frequency of adverse events.
RESULTS: Both MM and EL regimens were effective, with successful abortion rates of 96.19% and 94.29%, respectively (P=0.746). The complete abortion rates were 68.57% and 70.48%, respectively. The induction-to-abortion interval was longer in the MM group than in the EL group (50.57+/-6.80 h vs. 43.02+/-8.74 h, respectively, P<0.001). Both treatments were safe, although there was a significant difference in rates of gastrointestinal and fever adverse events between the two groups.
CONCLUSIONS: Both MM and EL regimens were effective with high success rates and were safe for the termination of second trimester pregnancy. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434827     DOI: 10.1016/j.ejogrb.2010.04.004

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  5 in total

1.  Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells.

Authors:  Lianne E Rotin; Neil MacLean; Ahmed Aman; Marcela Gronda; Feng-Hsu Lin; Rose Hurren; XiaoMing Wang; Jeffrey L Wrana; Alessandro Datti; Rima Al-Awar; Mark D Minden; Aaron D Schimmer
Journal:  Haematologica       Date:  2016-09-01       Impact factor: 9.941

2.  Effectiveness and safety of double-balloon catheter versus intra-amniotic injection of ethacridine lactate for termination of second trimester pregnancy in patients with liver dysfunction.

Authors:  Na Li; Peng Wu; Jie Zhao; Ling Feng; Fu-Yuan Qiao; Wan-Jiang Zeng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-02-12

Review 3.  Medical methods for mid-trimester termination of pregnancy.

Authors:  Hajo Wildschut; Marieke I Both; Suzanne Medema; Eeke Thomee; Mark F Wildhagen; Nathalie Kapp
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

4.  Misoprostol versus High Dose Oxytocin and Laminaria in Termination of Pregnancy in Second Trimester Pregnancies.

Authors:  Azin Alavi; Minoo Rajaei; Malihe Amirian; Lili Nikuee Ghazvini
Journal:  Electron Physician       Date:  2013-11-01

5.  Clinical analyses of 66 cases of mid-trimester pregnancy termination in women with prior cesarean.

Authors:  Ping Peng; Xin-Yan Liu; Lei Li; Li Jin; Wei-Lin Chen
Journal:  Chin Med J (Engl)       Date:  2015-02-20       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.